HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
Focal apical hypertrophy with ace of spades morphology reinforces the diagnostic value of echocardiography in suspected hypertrophic cardiomyopathy.
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it ...
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that three abstracts featuring Viz HCM, the company’s AI-powered ECG analysis and care ...
HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to ...
Romano-Ward syndrome, the most common congenital long QT disorder, often causes exertion- or stimulus-triggered syncope and ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that management will attend key investor and ...
The hand-held, artificial intelligence-enabled electrocardiogram, or ECG for short, has the ability to process the data as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results